PacBio Increases IPO Target Amount to $230M

The firm, which also disclosed that it had undergone a 1-for-2 reverse stock split in September, had previously said its IPO could raise as much as $200 million.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories